Navigation Links
The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment
Date:9/30/2011

THE WOODLANDS, Texas, Sept. 30, 2011 /PRNewswire/ -- David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

(Logo: http://photos.prnewswire.com/prnh/20110916/MM70140LOGO)

"Being treated with PROVENGE was an excellent experience," said David. "I had no side effects, and I still feel as good as I did before diagnosis. My family and I are hopeful for the future. Because I was able to get this cutting-edge treatment, I am optimistic I will see my first grandchild."

David was treated at Blue Ridge Cancer Care, an affiliate of The US Oncology Network, one of the nation's largest networks of community-based oncologists dedicated to advancing cancer care in America. The US Oncology Network announced during Prostate Cancer Awareness Month that many of its affiliated practices are among the first in the nation to treat advanced prostate cancer patients with PROVENGE.

"We in The Network pride ourselves on being at the forefront of cutting-edge cancer treatments so our patients can get high-quality cancer care," said Amit Mehta, M.D., Medical Director of Research for Regional Cancer Care, an affiliate of The US Oncology Network. "Several exciting novel therapies have recently been approved for prostate cancer, and we are excited to be among the first sites in the nation to offer PROVENGE, giving patients complete prostate cancer care."

At least 17 practices affiliated with The US Oncology Network offer PROVENGE and have treated prostate cancer patients with the drug when appropriate. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

"PROVENGE is the first type of therapy that uses my own cells to work against the cancer cells," said Donald Larrick, a prostate cancer patient being treated at Virginia Cancer Specialists, an affiliate of The US Oncology Network. "I believe that it is decreasing the load of my cancer."

PROVENGE is an autologous (made from a patient's own immune cells) cellular immunotherapy designed to stimulate a patient's immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

"This is an exciting new therapy that gives new options to men with advanced prostate cancer," says Joseph Volk, M.D., oncologist with Arizona Oncology, an affiliate of The US Oncology Network. "In the future, we will be able to use targeted therapies to treat different types of cancer. We're pleased to be able to provide this option to our patients."

The US Oncology Network affiliated practices offering PROVENGE include:-Advanced Medical Specialties

-Arizona Oncology-Blue Ridge Cancer Care

-Cancer Centers of North Carolina-Cancer Centers of North Carolina-Asheville

-Cancer Centers of the Carolinas-Comprehensive Cancer Care-St. Louis

-Comprehensive Cancer Centers of Nevada-Minnesota Oncology

-Northwest Cancer Specialists-Ocala Oncology Center

-Regional Cancer Care-Texas Oncology

-Virginia Cancer Specialists-Virginia Oncology Associates

-Wilshire Oncology Medical Group-Willamette Valley Cancer Institute and Research CenterPROVENGE Safety PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events.  Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.  Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see full Prescribing Information for PROVENGE at www.provenge.com.

About Prostate CancerAccording to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 240,890 new cases and approximately 33,720 men expected to die from the disease this year.

Individuals interested in learning whether PROVENGE is an appropriate treatment option should contact one of the practices listed above or call 1-877-336-3736.  For full Prescribing Information, please visit www.PROVENGE.com.

About The US Oncology NetworkThe US Oncology Network is one of the nation's largest networks of community-based oncology physicians dedicated to advancing cancer care in America. Like-minded physicians are united through The Network around a common vision of expanding patient access to high-quality, integrated cancer care in communities throughout the nation. Leveraging healthcare information technology, shared best practices, refined evidence-based medicine guidelines, and quality measurements, physicians affiliated with The US Oncology Network are committed to advancing the quality, safety, and science of cancer care to improve patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system to advance the science, technology and quality of care. For more information, visit www.usoncology.com.


'/>"/>

SOURCE The US Oncology Network
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... still in shock after receiving a $2,500 Academic Award from California Casualty . “This ... She thinks the coming week is going to be a very joyful for her classroom. ... students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary School ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy ... resolve the pending litigation between itself and 1800 Vending DBA Healthy You Vending. ... “I am thrilled to announce that we have now reached a settlement agreement ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
(Date:3/24/2017)... York, NY (PRWEB) , ... March 24, 2017 ... ... campaign: “Fighting Infection,” which will spark a conversation on the current obstacles facing ... the number of completely preventable deaths caused by these infections. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio and ... Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
Breaking Medicine News(10 mins):